View profile

FarmaKology Newsletter - Issue #74



June 9 · Issue #74 · View online

FarmaKology is a newsletter that brings you the latest news, research, job opportunities in the Pharma world, and much more! If you would like to be featured in the newsletter, sponsor an issue, or need anything, please feel free to get in touch with me at "".

Would you like to submit an article, some interesting news, or get your startup featured? Send whatever you have to, and happy to have you featured on our newsletter (+10K Subscribers )!

Today's Startup
uFraction8 builds products around a disruptive new liquid particle processing technology. Following our world-leading research, establishing new levels of throughput for massively multiplexed microfluidic devices, our technology will be the key to unlock a prosperous and sustainable future. Our technology offers superior performance and costs savings against the big three liquid processing technologies of filtration, flow centrifugation, and flocculation. High volume applications benefit from our unique ability to granularly match targeted volumetric throughputs and our ability to scale this beyond the physical limitations of competing technologies.
 Biogen and Eisai, Co., Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for ADUHELM™ (aducanumab-avwa) as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease by reducing amyloid-beta plaques in the brain.
 Bayer AG announced today that BlueRock Therapeutics, a clinical-stage biopharmaceutical company and a wholly-owned subsidiary of Bayer AG, successfully administered the first dose of its pluripotent stem cell-derived dopaminergic neurons, named DA01, to a Parkinson’s disease patient in their open-label Phase 1 clinical study. In parallel a gene therapy program also targeted at providing advanced therapies for Parkinson’s disease is driven forward by Bayer’s wholly-owned clinical-stage adeno-associated virus gene therapy company Asklepios BioPharmaceutical, Inc. . This program is currently recruiting and evaluating patients in an ongoing Phase 1b clinical study.
CareDx, Inc., a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it has acquired Transplant Hero LLC, a New York-based provider of a mobile application supporting the needs of transplant patients.
 Roche today announced it has received CE mark for its SARS-CoV-2 Antigen Self Test Nasal for at-home testing. The test will be available in countries accepting the CE mark through pharmacies and other locations, in packs of five tests.
Research & Study
Documenting Value| Samm Anderegg, PharmD, CEO At DocStation The Business Of Pharmacy podcast
Job Opportunities
Upcoming Webinar
Antibiotic Classes in 7 minutes!!
Did you enjoy this issue?
In order to unsubscribe, click here.
If you were forwarded this newsletter and you like it, you can subscribe here.
Powered by Revue